Introduction {#s1}
============

The transcription factor 7-like 2 (*TCF7L2*) gene, previously reported as *TCF-4*, has been found to be associated with type 2 diabetes. Rs7903146 variant of *TCF7L2* gene was firstly identified as one susceptibility marker of type 2 diabetes by genome-wide association study [@pone.0071730-Salonen1]. The following studies further confirmed the association between *TCF7L2* rs7903146 variant and type 2 diabetes [@pone.0071730-Peng1]. In addition, individuals carrying T alleles of *TCF7L2* rs7903146 variant demonstrated high risk of insulin resistance [@pone.0071730-Lyssenko1]. Alternatively, *TCF7L2* may affect cancer independently of diabetes, as the *TCF7L2* gene product is involved the Wnt/β-catenin signaling pathway. TCF7L2 forms an active nuclear complex with β-catenin that binds and induces the expression of target genes involved in cellular proliferation, evasion of apoptosis, and tissue invasion and metastasis.

To date, many studies have been published investigating the association between *TCF7L2* rs7903146 or rs12255372 (it is in high linkage disequilibrium with rs7903146) and several types of cancer, including breast cancer [@pone.0071730-Burwinkel1]--[@pone.0071730-Connor1], prostate cancer [@pone.0071730-Folsom1], [@pone.0071730-Agalliu1]--[@pone.0071730-Machiela1], colorectal cancer [@pone.0071730-Folsom1], [@pone.0071730-Hazra1]--[@pone.0071730-Sainz1], colon cancer [@pone.0071730-Folsom1], [@pone.0071730-Slattery1], lung cancer [@pone.0071730-Folsom1] and ovarian cancer [@pone.0071730-Goode1]. However, the conclusions have been conflicting. Therefore, we performed a meta-analysis to clarify the association between *TCF7L2* rs7903146 variant and cancer risk.

Materials and Methods {#s2}
=====================

Literature and Search Strategy {#s2a}
------------------------------

We searched the PubMed and EMBASE literature databases. The search strategy to identify all possible studies involved the use of the following key words: (*TCF7L2* or transcription factor 7-like 2 or *TCF-4*) and (variant or variation or polymorphism or genotype) and (cancer or carcinoma or tumor). All related studies published in English language were included. The reference lists of retrieved articles were hand-searched. If more than one article were published using the same case series, only the study with the latest data was included. The literature search was updated on February 18, 2013.

Inclusion Criteria and Data Extraction {#s2b}
--------------------------------------

The studies included in the meta-analysis must meet all the following inclusion criteria: (1) evaluates the associations of *TCF7L2* polymorphism with cancer risk; (2) uses case--control or cohort design; and (3) provides sufficient data for calculation of odds ratio (OR) with 95% confidence interval (CI). The following information was extracted from each study: (1) name of the first author; (2) year of publication; (3) country of origin; (4) ethnicity; (5) cancer type; (6) sample size of cases and controls; (7) covariates' adjusted OR with 95%CI under co-dominant model; (8) minor allele frequency in cases and controls; (9) *p* for Hardy Weinberg Equilibrium test in controls; and (10) studied polymorphism. The two authors independently assessed the articles for compliance with the inclusion/exclusion criteria, resolved disagreements and reached a consistent decision.

Statistical Analysis {#s2c}
--------------------

The association of *TCF7L2* polymorphism with cancer risk was estimated by calculating pooled ORs and 95%CIs under a co-dominant model. The significance of pooled OR was determined by Z test (P\<0.05 was considered statistically significant). Q test was performed to evaluate the between-study heterogeneity. A random- (DerSimonian-Laird method [@pone.0071730-DerSimonian1] or fixed- (Mantel--Haenszel method) [@pone.0071730-Mantel1] effects model was used to calculate pooled OR in the presence (*P*≤0.10) or absence (*P*\>0.10) of heterogeneity, respectively. Subgroup analysis by cancer type was performed to address the between-study heterogeneity. Publication bias was assessed by Begg's test [@pone.0071730-Begg1] and Egger's test [@pone.0071730-Egger1] (*P*\<0.05 was considered statistically significant). Data analysis was performed using STATA version 11 (StataCorp LP, College Station, TX, USA).

Results {#s3}
=======

Characteristics of the Studies {#s3a}
------------------------------

In this study, we followed the PRISMA Statement ([Checklist S1](#pone.0071730.s001){ref-type="supplementary-material"}). A flow chart describing the process of inclusion/exclusion of study is presented in [Fig. 1](#pone-0071730-g001){ref-type="fig"}. The literature search identified a total of 128 potentially relevant papers. Of them, 112 papers were excluded because of obvious irrelevance by reading the titles and abstracts. In addition, two papers were excluded because they were reviews. Then, 14 papers met the primary inclusion criteria. However, one paper was excluded because it did not provide sufficient data to calculate OR with 95%CI [@pone.0071730-Domenyuk1]. Since more than one study was included in two articles by Folsom et al [@pone.0071730-Folsom1] and Goode et al [@pone.0071730-Goode1], they were considered as separate studies in the meta-analysis. In addition, since rs7903146 was in high LD with rs12255372, we combined all the included studies together. At last, 19 studies for the association between *TCF7L2* polymorphism and cancer risk were included in the final meta-analysis. Of them, five were on breast cancer, five were on prostate cancer, four were on colorectal cancer, two were on colon cancer, two were on lung cancer, and one was on ovarian cancer. The characteristics of the included studies are listed in [Table 1](#pone-0071730-t001){ref-type="table"}. It should be noted that because most studies provided covariates' adjusted OR with 95%CI under a co-dominant model, we calculated the pooled estimate under this model only.

![Flow chart of meta-analysis for exclusion/inclusion of individual articles (or studies).](pone.0071730.g001){#pone-0071730-g001}
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###### Characteristics of included studied of association between *TCF7L2* rs7903146 (or its proxy rs12255372) polymorphism and cancer risk.

![](pone.0071730.t001){#pone-0071730-t001-1}

  Study             Country       Ethnicity         Cancer type      Sample size   Homogeneous co-dominant model   Heterogeneous co-dominant model    MAF    *P* for HWE   Studied SNP                                         
  ---------------- ---------- ----------------- ------------------- ------------- ------------------------------- --------------------------------- ------- ------------- ------------- ------- ------- ------ ------ -------- ------------
  Burwinkel,2006    Germany       European         Breast cancer         592                    735                             1.37                 0.91       2.08          1.21       0.97    1.53    0.29   0.26   0.643    rs12255372
  Agalliu,2008        USA         European        Prostate cancer        582                    540                             0.73                 0.44       1.20          0.94       0.72    1.23    0.27   0.29   0.777    rs12255372
  Folsom,2008a        USA           Mixed        Colorectal cancer       180                   11410                            1.56                 0.97       2.53          1.17       0.85    1.61    0.34   0.29   0.806    rs7903146
  Folsom,2008b        USA           Mixed          Colon cancer          128                                                    2.15                 1.27       3.64          1.25       0.85    1.83    0.36   0.29   0.806    rs7903146
  Folsom,2008c        USA         European          Lung cancer          177                                                    1.59                 0.96       2.63          1.63       1.17    2.25    0.37   0.29   0.806    rs7903146
  Folsom,2008d        USA           Black           Lung cancer          62                                                     0.62                 0.22       1.76          0.75       0.44     1.3    0.26   0.29   0.806    rs7903146
  Folsom,2008e        USA           Mixed          Breast cancer         342                                                    0.87                 0.57       1.32          0.98       0.78    1.23    0.28   0.29   0.806    rs7903146
  Folsom,2008f        USA           Mixed         Prostate cancer        366                                                    1.04                 0.72       1.50          0.80       0.64    0.99    0.27   0.29   0.806    rs7903146
  Hazra,2008          USA         European       Colorectal cancer       357                    814                             0.63                 0.37       1.08          0.90       0.68    1.18    0.25   0.29   0.497    rs12255372
  Slattery,2008       USA           Mixed          Colon cancer         1573                   1962                             1.03                 0.80       1.33          1.14       0.99    1.31    0.29   0.28   0.878    rs7903146
  Goode,2009a         USA         European         Breast cancer         779                    830                             0.92                 0.62       1.36          1.16       0.93    1.43     NA    0.28    0.23    rs12255372
  Goode,2009b         USA         European        Ovarian cancer         391                    458                             0.97                 0.56       1.68          0.95       0.71    1.26     NA    0.26    0.96    rs12255372
  Tsilidis,2009       USA           Mixed        Colorectal cancer       202                    354                             1.44                 0.81       2.57          1.13       0.78    1.66    0.32   0.28   0.196    rs7903146
  Wang,2009           USA           Mixed         Prostate cancer        249                    249                             0.62                 0.32       1.20          0.94       0.62    1.42    0.27   0.30   0.151    rs7903146
  Meyer,2010          USA           Mixed         Prostate cancer        365                   5757                           0.88 ^b^               0.75       1.03        0.88 ^b^     0.75    1.03     NA    0.30   \>0.05   rs7903146
  Machiela,2012       USA         European        Prostate cancer       2782                   4458                           0.90 ^b^               0.83       0.97        0.90 ^b^     0.83    0.97     NA    0.28   \>0.05   rs7903146
  Naidu,2012        Malaysia   Southeast Asian     Breast cancer         387                    252                             1.574                0.829      2.987         1.329      0.948   1.862   0.31   0.26   0.518    rs12255372
  Sainz,2012        Germany       European       Colorectal cancer      1764                   1749                             1.28                 1.01       1.63          1.13       0.98    1.30    0.31   0.28   0.435    rs7903146
  Connor,2012         USA           Mixed          Breast cancer        3523                   4209                             1.24                 1.03       1.49          1.09       0.99    1.20    0.26   0.23   0.121    rs7903146

Covariates' adjusted estimate ^b^ Estimate under an additive model.

MAF, minor allele frequency; NA, not available; HWE, Hardy Weinberg Equilibrium.

Meta-analysis Results {#s3b}
---------------------

A total of 14814 cases and 33856 controls were identified for the analysis of the association between *TCF7L2* polymorphism with cancer risk. The results indicated that *TCF7L2* polymorphism might not be associated with cancer risk under co-dominant model (Homogeneous model: OR = 1.07, 95%CI = 0.95--1.21, *I* ^2^ = 61.4%, *p* for heterogeneity\<0.001, [Figure 2](#pone-0071730-g002){ref-type="fig"}; Heterogeneous model: OR = 1.04, 95%CI = 0.97--1.12, *I* ^2^ = 58.1%, *p* for heterogeneity = 0.001, [Figure 3](#pone-0071730-g003){ref-type="fig"}). However, further subgroup analysis by cancer type suggested that the effect size was significant for breast cancer (Homogeneous model: OR = 1.17, 95%CI = 1.02--1.35, *I* ^2^ = 21.8%, *p* for heterogeneity = 0.276; Heterogeneous model: OR = 1.11, 95%CI = 1.03--1.20, *I* ^2^ = 0.0%, *p* for heterogeneity = 0.543), prostate cancer (Homogeneous model: OR = 0.89, 95%CI = 0.84--0.96, *I* ^2^ = 0.0%, *p* for heterogeneity = 0.640; Heterogeneous model: OR = 0.89, 95%CI = 0.84--0.95, *I* ^2^ = 0.0%, *p* for heterogeneity = 0.871), and colon cancer (Heterogeneous model: OR = 1.15, 95%CI = 1.01--1.31, *I* ^2^ = 0.0%, *p* for heterogeneity = 0.658), but not for colorectal cancer, lung cancer, and ovarian cancer (all *p*\>0.05, [Table 2](#pone-0071730-t002){ref-type="table"}).

![Meta-analysis of association between *TCF7L2* rs7903146 polymorphism and cancer risk under homogeneous co-dominant model.](pone.0071730.g002){#pone-0071730-g002}

![Meta-analysis of association between *TCF7L2* rs7903146 polymorphism and cancer risk under heterogeneous co-dominant model.](pone.0071730.g003){#pone-0071730-g003}
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###### Pooled ORs and 95%CIs of the association between *TCF7L2* rs7903146 (or its proxy rs12255372) polymorphism and cancer risk.

![](pone.0071730.t002){#pone-0071730-t002-2}

  Contrasts                   No. of studies (cases/controls)           Homogeneous co-dominant model   Heterogeneous co-dominant model                                              
  ------------------- ------------------------------------------------ ------------------------------- --------------------------------- ------ --------- ------ ------------ ------ -------
  All                                 19 (14814/33856)                              1.07                          0.95--1.21              61.4   \<0.001   1.04   0.97--1.12   58.1   0.001
  Cancer type                                                                                                                                                                        
  Breast cancer        5 (5623/17436)[a](#nt103){ref-type="table-fn"}               1.17                          1.02--1.35              21.8    0.276    1.11   1.03--1.20   0.0    0.543
  Prostate cancer      5 (4358/22493)[a](#nt103){ref-type="table-fn"}               0.89                          0.84--0.96              0.0     0.640    0.89   0.84--0.95   0.0    0.871
  Colorectal cancer    4 (2502/14327)[a](#nt103){ref-type="table-fn"}               1.18                          0.84--1.66              59.1    0.062    1.09   0.98--1.22   0.0    0.507
  Colon cancer         2 (1710/13372)[a](#nt103){ref-type="table-fn"}               1.43                          0.70--2.94              83.6    0.014    1.15   1.01--1.31   0.0    0.658
  Lung cancer          2 (239/11410)[a](#nt103){ref-type="table-fn"}                1.11                          0.45--2.73              60.8    0.110    1.14   0.53--2.44   82.7   0.016
  Ovarian cancer                        1 (391/458)                                 0.97                          0.56--1.68               --      --      0.95   0.71--1.27    --     --

Shared the same number of controls (*n* = 11410).

Potential Publication Bias {#s3c}
--------------------------

No publication bias could be detected under homogeneous co-dominant model (*p* = 0.780 for Begg's test and *p* = 0.123 for Egger's test) and heterogeneous co-dominant model (*p* = 0.889 for Begg's test and *p* = 0.274 for Egger's test).

Discussion {#s4}
==========

To the best of our knowledge, our meta-analysis represents the first one investigating the association between *TCF7L2* rs7903146 polymorphism and cancer risk. The results suggested that *TCF7L2* rs7903146 polymorphism might not be associated with cancer risk. However, further stratified analysis demonstrated the significant association with breast cancer, prostate cancer and colon cancer, rather than colorectal cancer, lung cancer, and ovarian cancer.

Interestingly, the T allele of rs7903146 polymorphism, which has been associated with increased risk of type 2 diabetes, showed the inverse association with prostate cancer based on our meta-analysis. The finding was consistent with those from the individual studies by Folsom et al. [@pone.0071730-Folsom1] and Machiela et al [@pone.0071730-Machiela1]. However, the other three included studies did not suggest any association [@pone.0071730-Agalliu1]--[@pone.0071730-Meyer1]. In addition, we found positive association between rs7903146 polymorphism and breast cancer risk. Recently, Michailidou K et al. [@pone.0071730-Michailidou1] have found rs7904519 in intron 4 of *TCF7L2* (r^2^ = 0.37 with rs7904519/rs12255372), to be associated with breast cancer. Further studies are necessary to examine the potential different mechanisms of *TCF7L2* polymorphism in various cancers.

Heterogeneity between studies is common in meta-analysis of genetic association studies. Although heterogeneity can be taken into account by performing a random-effects model, it would increase the odds of type I error [@pone.0071730-Munaf1]. We found significant between-study heterogeneity in the association of *TCF7L2* rs7903146 polymorphism with cancer risk. Therefore, subgroup analysis by cancer types was performed to explore the source of heterogeneity. The results showed that the between-study heterogeneity disappeared in several subgroups, but remained in other subgroups suggesting other covariates might confound the association.

The current meta-analysis has several strengths. First, OR (95% CI) after covariates adjustment from individual study was used to calculate the pooled the estimate, which increased the accuracy of effect estimate. Second, statistical power was greatly improved for the association study of *TCF7L2* rs7903146 polymorphism in the pooled analysis. However, several limitations should also be noted. First, the case -- control study design does not allow for the inference of causality between the gene polymorphism and the outcome. Second, the effect of gene -- gene/gene -- environment interactions was not addressed in this meta-analysis. Third, although ethnicity plays an important role in the association of *TCF7L2* rs7903146 polymorphism with cancer risk, we did not perform the further subgroup analysis by ethnicity because of limited studies for each cancer type.

In conclusion, the results indicated that there was a significantly association between *TCF7L2* rs7903146 polymorphism and the risk of breast cancer, prostate cancer and colon cancer, rather than colorectal cancer, lung cancer, and ovarian cancer. Further well-designed large-scale studies with the consideration of gene--gene and gene--environment interactions should be conducted to investigate the association in future.
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